Senior Pharma Executive Joins LAB International's Pharma Team
News Oct 13, 2005
LAB International Inc. has announced the appointment of Dr. Antti Jekunen to LAB Pharma's senior management team as Senior Vice-President, Clinical and Regulatory Affairs.
Prior to joining LAB International, Dr. Jekunen served as Director, clinical oncology, drug design and development at Brystol-Myers Squibb Pharmaceutical USA, Senior Director in clinical drug development at Ilex Oncology and as Medical Director at Aventis Pharma Finland.
Dr Jekunen brings 15 years of academic and pharmaceutical industry experience of drug development to LAB.
He has been directly responsible for the development and implementation of the clinical and regulatory strategies of several of Rhône-Poulenc Rorer, Aventis and BMS drugs both in Europe and in the US.
"We are very pleased to have Dr. Jekunen join the LAB Pharma executive team. Dr Jekunen brings to LAB a vast and in depth international clinical drug design and development experience acquired at major pharmaceutical companies," said Dr. Halvor Jaeger, Chief Executive Officer of LAB International.
"He will play a key role in our product development programs and regulatory processes as more of our drugs advance into late stage clinical stages."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE